Clifford is a Research Fellow at UniSA Clinical & Health Sciences.
He obtained a PhD in Biochemistry from Victoria University of Wellington after using gel-based proteomics to study the cellular effects of an algal toxin. His interests in proteomic technologies led the New Zealander to Denmark, where he spent time at the University of Southern Denmark and University of Copenhagen learning and implementing strategies to investigate the biological roles of protein post-translational modifications. These chemical additions are notoriously difficult to study because of their low abundance, which often require enrichment protocols and detection by high resolution mass spectrometry. Clifford also has extensive experience with liquid ... Read more
About me
Clifford is a Research Fellow at UniSA Clinical & Health Sciences.
He obtained a PhD in Biochemistry from Victoria University of Wellington after using gel-based proteomics to study the cellular effects of an algal toxin. His interests in proteomic technologies led the New Zealander to Denmark, where he spent time at the University of Southern Denmark and University of Copenhagen learning and implementing strategies to investigate the biological roles of protein post-translational modifications. These chemical additions are notoriously difficult to study because of their low abundance, which often require enrichment protocols and detection by high resolution mass spectrometry. Clifford also has extensive experience with liquid chromatography and Orbitrap mass spectrometers, as well as performing selected/parallel reaction monitoring for the quantification of peptides and metabolites.
Clifford joined the Future Industries Institute (UniSA STEM) in 2018 before moving to UniSA Clinical & Health Sciences in 2021. He is enthusiastic about scientific collaborations with research groups and industrial companies in South Australia. Interested parties are welcome to contact Clifford for initial discussions.
Research
Research outputs for the last seven years are shown below. Some long-standing staff members may have older outputs included. To see earlier years visit ORCID or Scopus
Open access indicates that an output is open access.
| Year | Output |
|---|---|
| 2023 |
Open access
|
| 2023 |
Open access
|
| 2023 |
Open access
2
4
|
| 2022 |
Open access
8
7
8
|
| 2022 |
Open access
1
1
|
| 2022 |
Open access
3
1
5
|
| 2022 |
1
1
1
|
| 2021 |
20
1
|
| 2021 |
Open access
9
4
|
| 2021 |
Open access
9
6
4
|
| 2017 |
221
199
13
|
| 2017 |
9
9
9
|
| 2016 |
Open access
141
87
1
|
| 2015 |
Open access
43
40
2
|
| 2015 |
Open access
50
44
11
|
External engagement & recognition
| Organisation | Country |
|---|---|
| Evosep Biosystems | DENMARK |
| Leiden University | NETHERLANDS |
| Macquarie University | AUSTRALIA |
| Norwegian University of Science and Technology NTNU | NORWAY |
| Novo Nordisk (Denmark) | DENMARK |
| Royal Adelaide Hospital | AUSTRALIA |
| University of Adelaide | AUSTRALIA |
| University of Copenhagen | DENMARK |
| University of Erlangen-Nuremberg | GERMANY |
| University of Melbourne | AUSTRALIA |
| University of Queensland | AUSTRALIA |
| University of Science, Malaysia | MALAYSIA |
| University of South Australia | AUSTRALIA |
| University of Southern Denmark | DENMARK |
| University of Sydney | AUSTRALIA |
| University of Zurich | SWITZERLAND |
Teaching & student supervision
Supervisions from 2010 shown
| Thesis title | Student status |
|---|---|
| 111153 - Mass Spectrometry assays for protein biomarker for the early detection of ovarian cancer | Current |
| Advancing Protein Therapeutic Development | Current |
| Functional Analysis and Quantification of Biopharmaceuticals in Tissues by Mass Spectrometry Imaging | Current |
| Maximising yeast health during the industrial beer brewing process: a proteomics investigation | Current |
| PAT Spectroscopic and MS techniques for near/real-time product characterisation for plasmaderived products | Current |
| PAT Spectroscopic and MS techniques fornear/real-time product characterisation for plasma derived products | Current |
